Chronic Hepatitis B Management in Transition | New HBV Guidelines 2024–2025 | Prof. Javed FAROOQI

Chronic Hepatitis B management is changing. Are we ready to translate the new guidelines into everyday clinical practice? In this lecture series, I discuss the evolving approach to Chronic Hepatitis B (CHB) management, with particular emphasis on translating contemporary international recommendations into practical decision-making in resource-limited settings such as Pakistan. The discussion integrates key concepts from the WHO 2024, EASL 2025, and AASLD/IDSA guidance, focusing on how newer recommendations are expanding treatment eligibility and moving HBV care toward a more pragmatic, risk-based approach. Topics covered across the series include treatment eligibility, assessment of fibrosis and cirrhosis, management when HBV DNA or advanced investigations are unavailable, antiviral selection, monitoring, HDV screening, HCC surveillance, special clinical situations, and the future direction of HBV therapy. 🎓 Target audience: Physicians, gastroenterologists, hepatologists, internists, postgraduate trainees, family physicians, and medical students. 🎤 Lecture: Chronic Hepatitis B Management in Transition: Translating New HBV Guidelines into Clinical Practice in Resource-Limited Settings 📍 Presented in connection with the Annual Conference of the Pakistan Society of Hepatology, Karachi – 2026 📺 Medicine Made Easy — Educational Lectures for Doctors Disclaimer: This content is intended for medical education and should be interpreted alongside current guidelines, local resources, regulatory approvals, and individual patient circumstances. #ChronicHepatitisB #HepatitisB #HBV #HBVGuidelines #Hepatology #LiverDisease #WHO2024 #EASL2025 #AASLD #ClinicalPractice #MedicalEducation #Gastroenterology #PakistanHepatology #MedicineMadeEasy